3.15

2.17% -0.07

After Hours: 3.15

Acelyrin Inc (SLRN)

Overview News Price History Option Chain Why SLRN Down? Discussions Forecast

Acelyrin Inc stock is traded at $3.15, with a volume of 933.80K. It is down -2.17% in the last 24 hours and down -28.89% over the past month. Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.

Previous Close:

$3.22

Open:

$3.18

24h Volume:

933.80K

Relative Volume:

1.33

Market Cap:

$316.03M

Revenue:

Net Income/Loss:

$-299.80M

P/E Ratio:

-0.2599

EPS:

-12.1221

Net Cash Flow:

$-217.49M

1W Performance:

-2.48%

1M Performance:

-28.89%

6M Performance:

-20.85%

1Y Performance:

-55.76%

1-Day Range:

$3.105

$3.25

1-Week Range:

$3.105

$3.60

52-Week Range:

$3.105

$8.885

Acelyrin Inc Stock (SLRN) Company Profile

Name

Acelyrin Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

805-871-4300

Address

4149 LIBERTY CANYON RD., AGOURA HILLS

Employee

130

Twitter

Next Earnings Date

2024-12-13

Latest SEC Filings

SLRN's Discussions on Twitter

Compare SLRN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLRN Acelyrin Inc	3.15	316.03M	0	-299.80M	-217.49M	-2.84
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Acelyrin Inc Stock (SLRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-14-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-08-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-13-23	Initiated	Wells Fargo	Equal Weight
Dec-08-23	Initiated	Citigroup	Neutral
Sep-13-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-05-23	Initiated	H.C. Wainwright	Buy
May-30-23	Initiated	Jefferies	Buy
May-30-23	Initiated	Morgan Stanley	Overweight
May-30-23	Initiated	Piper Sandler	Overweight
May-30-23	Initiated	TD Cowen	Outperform

View All

Acelyrin Inc Stock (SLRN) Latest News

Dec 19, 2024

Fmr LLC Sells 4,596,424 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World

Dec 19, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Fmr LLC - MarketBeat

Dec 19, 2024

Dec 15, 2024

Charles Schwab Investment Management Inc. Acquires 273,604 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World

Dec 15, 2024

Dec 14, 2024

SLRN stock touches 52-week low at $3.18 amid market challenges - Investing.com Australia

Dec 14, 2024

Dec 13, 2024

Acelyrin (NASDAQ:SLRN) Earns “Neutral” Rating from HC Wainwright - Defense World

Dec 13, 2024

Dec 12, 2024

Acelyrin shares retain neutral rating despite trial setback By Investing.com - Investing.com UK

Dec 11, 2024

Acelyrin price target lowered to $13 from $15 at Wells Fargo - TipRanks

Dec 11, 2024

Point72 Asset Management L.P. Has $1.23 Million Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Dec 11, 2024

Acelyrin shares tumble after decision to halt izokibep development on failing trial - Seeking Alpha

Dec 11, 2024

Dec 10, 2024

Acelyrin Shares Fall After Halting Development of Eye Disease Treatment - MarketWatch

Dec 10, 2024

Acelyrin Finance Chief Gil Labrucherie to Exit - MarketWatch

Dec 10, 2024

Acelyrin announces izokibep trial did not meet primary endpoint - TipRanks

Dec 10, 2024

ACELYRIN Faces CFO Resignation and Trial Setback - TipRanks

Dec 10, 2024

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis - The Manila Times

Dec 10, 2024

Dec 09, 2024

Acelyrin: Abandoned Programs Do Not Give Confidence (NASDAQ:SLRN) - Seeking Alpha

Dec 09, 2024

Dec 07, 2024

Polar Asset Management Partners Inc. Sells 150,700 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Dec 07, 2024

Dec 06, 2024

Jacobs Levy Equity Management Inc. Sells 153,465 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Dec 06, 2024

Nov 28, 2024

Acuta Capital Partners LLC Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Nov 28, 2024

Nov 22, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Nov 22, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.50 Consensus Price Target from Analysts - MarketBeat

Nov 22, 2024

Nov 18, 2024

HC Wainwright Issues Positive Estimate for Acelyrin Earnings - MarketBeat

Nov 18, 2024

Nov 15, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

TD Cowen maintains Buy rating on Acelyrin shares By Investing.com - Investing.com Canada

Nov 15, 2024

Acelyrin discloses ValenzaBio acquisition financials - Investing.com India

Nov 15, 2024

Nov 14, 2024

TD Cowen maintains Buy rating on Acelyrin shares - Investing.com

Nov 14, 2024

T. Rowe Price Investment Management, Inc. Reduces Stake in Acely - GuruFocus.com

Nov 14, 2024

Earnings call: Acelyrin focuses on TED treatment, eyes Phase 3 trials - Investing.com

Nov 14, 2024